Treatment of 2019-nCoV Pneumonia with N-acetylcysteine

Not Applicable

• Conditions: Severe acute respiratory syndrome; Viral Pneumonia; J12.8

• Registration Number: RBR-8969zg
• Lead Sponsor: niversidade de São Paulo

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-04-13
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Volunteers; Both genders; Admitted to the Emergency Department with diagnosis of Acute Respiratory Syndrome, presumed or confirmed; Age equal to or greater than 18 years; Informed consent form (ICF) signed by the patient or legal guardian.

Exclusion Criteria

Patients with known allergy to N acetylcysteine; Pregnant women; In need of immediate mechanical ventilation or Refusal or inability to obtain consent

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Reduction in in-hospital mortality in 5%, verified by medical record analysis, in patients receiving N-acetylcysteine compared to the group receiving Placebo

Secondary Outcome Measures

Name	Time	Method
Reduction in 5% in the need for endotracheal intubation, verified by medical record analysis, in patients receiving N-acetylcysteine compared to the group receiving Placebo